Pioglitazone opposes neurogenic vascular dysfunction associated with chronic hyperinsulinaemia

British Journal of Pharmacology

Volumn 153, Issue 7, 2008, Pages 1388-1398

  Takatori, S ^a,b   Zamami, Y ^a   Yabumae, N ^a   Hanafusa, N ^a   Mio, M ^c   Egawa, T ^c   Kawasaki, H ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NIPPON SHINYAKU CO LTD   (Japan)

^c SHUJITSU UNIVERSITY   (Japan)

Author keywords

Adrenergic nerve mediated pressor; Calcitonin gene related peptide containing nerve mediated depressor; Chronic hyperinsulinaemia; Pioglitazone; Pithed rat; Spinal cord stimulation

Indexed keywords

ANGIOTENSIN II; CHOLESTEROL; NORADRENALIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEART RATE; HYPERTENSION; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD STIMULATION;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; HYPERINSULINISM; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; NOREPINEPHRINE; RANDOM ALLOCATION; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TRIGLYCERIDES; VASOCONSTRICTION;

EID: 41649103676     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.8     Document Type: Article

References (39)

1. Anan F, Masaki T, Fukunaga N, Teshima Y, Iwao T, Kaneda K et al. (2007). Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest 37: 709-714.
2. Buchnan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL et al. (1995). Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96: 354-360.
3. Campbell IW (2005). The clinical significance of PPAR gamma agonism. Curr Mol Med 5: 349-363.
4. Defronzo RA (1981). The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia 21: 165-171.
5. De Rivas B, Luque M, Martell N, Fernandez C, Fernandez-Cruz A (2007). Pioglitazone decreases ambulatory blood pressure in type 2 diabetes with difficult-to-control hypertension. J Clin Hypertens 9: 530-537.
6. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H (1997). Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30: 1144-1149.
7. Forst T, Hohberg C, Fuellert SD, Lubben G, Konrad T, Lobig M et al. (2005). Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 37: 521-527.
8. Grinsell JW, Lardinois CK, Swislocki A, Gonzalez R, Sare JS, Michaels JR et al. (2000). Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am J Hypertens 13: 370-375.
9. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP (1992). Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41: 715-722.
10. Hsueh WA, Law RE (1999). Insulin signaling in the arterial wall. Am J Cardiol 84: 21-24.
11. Kato K, Satoh H, Endo Y, Yamada D, Midorikawa S, Sato W et al. (1999). Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 258: 431-435.
12. Kaufman LN, Peterson MM, Degrange LM (1995). Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44: 1105-1109.
13. Kawasaki H, Nuki C, Saito A, Takasaki K (1990). Role of calcitonin gene-related peptide-containing nerves in the vascular adrenergic neurotransmission. J Pharmacol Exp Ther 252: 403-409.
14. Kawasaki H, Takasaki K (1986). Central alpha-2 adrenoceptor-mediated hypertensive response to clonidine in conscious, normotensive rats. J Pharmacol Exp Ther 236: 810-818.
15. Kawasaki H, Takasaki K, Saito A, Goto K (1988). Calcitonin generelated peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 335: 164-167.
16. Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H et al. (2004). Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47: 2215-2225.
17. Kotchen TA, Reddy S, Zhang HY (1997). Increasing insuline sensitivity lowers blood pressure in the fructose fed rats. Am J Hypertens 10: 1020-1026.
18. Landsberg L (1986). Diet, obesity and hypertension: a hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 61: 1081-1090.
19. Lembo G, Napoli R, Capaldo B, Rendina V, Iaccarino G, Volpe M et al. (1992). Abnormal sympathetic overactivity evoked by insulin in skeletal muscle of patients with essential hypertension. J Clin Invest 90: 24-29.
20. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000). Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531.
21. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H (1992). Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 20: 797-801.
22. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J (1998). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103.
23. Mimaki Y, Kawasaki H, Okazaki M, Nakatsuma A, Araki H, Gomita Y (1998). Involvement of calcitonin gene-related peptide (CGRP) receptors in insulin-induced vasodilatation in mesenteric resistance blood vessels of rats. Br J Pharmacol 123: 1684-1690.
24. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi M et al. (1985). Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75: 809-817.
25. Nuki C, Kawasaki H, Takasaki K, Wada A (1994). Pharmacological characterization of presynaptic calcitonin gene-related peptide (CGRP) receptors on CGRP-containing vasodilator nerves in rat mesenteric resistance vessels. J Pharmacol Exp Ther 268: 59-64.
26. Nuki Y, Kawasaki H, Taguchi T, Takasaki K, Wada A (1993). Effects of dorsal rhizotomy on depressor response to spinal cord stimulation mediated by endogenous calcitonin gene-related peptide in the pithed rat. J Neurosurg 79: 899-904.
27. Pasceri V, Wu HD, Willerson JT, Yen ET (2000). Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101: 235-238.
28. Reaven GM, Hoffman BB (1987). A role for insulin in the aetiology and course of hypertension? Lancet 2: 435-437.
29. Skarfors ET, Lithell HO, Selinus I (1991). Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 9: 217-223.
30. Suzuki M, Nomura C, Odaka H, Ikeda H (1997). Effect of an insulin sensitizer, pioglitazone, on hypertension in fructose-drinking rats. Jpn J Pharmacol 74: 297-302.
31. Taguchi T, Kawasaki H, Imamura T, Takasaki K (1992). Endogenous calcitonin gene-related peptide mediates nonadrenergic noncholinergic depressor response to spinal cord stimulation in the pithed rat. Circ Res 71: 357-364.
32. Takatori S, Mizote M, Zamami Y, Kurosaki Y, Kawasaki H (2003). Effects of insulin on vascular responses to spinal cord stimulation and vasoactive agents in pithed rats. Br J Pharmacol 140: 1137-1145.
33. Takatori S, Zamami Y, Mio M, Kurosaki Y, Kawasaki H (2006). Chronic hyperinsulinemia enhances adrenergic vasoconstriction and decreases calcitonin gene-related peptide-containing nerve-mediated vasodilation in pithed rats. Hypertens Res 29: 361-368.
34. Takenaga M, Kawasaki H (1999). Endogenous calcitonin gene-related peptide suppresses vasoconstriction mediated by adrenergic nerves in rat mesenteric resistance blood vessels. Eur J Pharmacol 367: 239-245.
35. Tanaka T, Fukunaga Y, Itoh H, Doi K, Yamashita J, Chun TH et al. (2005). Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 508: 255-265.
36. Tobey TA, Mondon CE, Zavaroni I, Reaven GM (1982). Mechanism of insulin resistance in fructose-fed rats. Metabolism 31: 608-612.
37. Uchida A, Nakata T, Hatta T, Kiyama M, Kawa T, Morimoto S et al. (1997). Reduction of insulin resistance attenuates the development of hypertension in sucrose-fed SHR. Life Sci 61: 455-464.
38. Verma S, Bhanot S, Arikawa E, Yao L, Mcneill JH (1998). Direct vasodepressor effects of pioglitazone in spontaneously hypertensive rats. Pharmacology 56: 7-16.
39. Zhang HY, Reddy SR, Kotchen TA (1994). Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 24: 106-110.